Top

Journal of Autism and Developmental Disorders

Gepubliceerd in:

08-07-2020 | Brief Report

Brief Report: Intranasal Ketamine in Adolescents and Young Adults with Autism Spectrum Disorder—Initial Results of a Randomized, Controlled, Crossover, Pilot Study

Auteurs: Logan K. Wink, Debra L. Reisinger, Paul Horn, Rebecca C. Shaffer, Kaela O’Brien, Lauren Schmitt, Kelli R. Dominick, Ernest V. Pedapati, Craig A. Erickson

Gepubliceerd in: Journal of Autism and Developmental Disorders | Uitgave 4/2021

Abstract

Dysregulation of glutamate neurotransmission plays a critical role in autism spectrum disorder (ASD) pathophysiology and is a primary target for core deficit research treatment trials. The mechanism of action of ketamine has striking overlap with the theory of ASD as a disorder of synaptic communication and neuronal networks. This two-dose, double-blind, placebo controlled, cross-over pilot trial of intranasal (IN) ketamine targeting core social impairment included individuals with ASD (N = 21) between 14 and 29 years. Participants were randomized to received two doses of IN ketamine (30 and 50 mg) and two doses of matching placebo. No significant impact was noted on the Aberrant Behavior Checklist Social Withdraw subscale. The IN ketamine was well tolerated, with only transient mild adverse effects.

vorige artikel Brief Report: What Happens After School? Exploring Post-school Outcomes for a Group of Autistic and Non-autistic Australian Youth

volgende artikel Brief Report: Cumulative Incidence of Autism Spectrum Disorder Before School Entry in a Thoroughly Screened Population

Aan Het Rot, M., Zarate, C. A., Jr., Charney, D. S., & Mathew, S. J. (2012). Ketamine for depression: Where do we go from here? Biological Psychiatry, 72, 537–547. https://doi.org/10.1016/j.biopsych.2012.05.003.CrossRefPubMedPubMedCentral

Aman, M. G., Singh, N. N., Stewart, A. W., & Field, C. J. (1985). The Aberrant Behavior Checklist: A behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency, 5, 485–491.

Anagnostou, E., Jones, N., Huerta, M., Halladay, A. K., Wang, P., Scahill, L., et al. (2015). Measuring social communication behaviors as a treatment endpoint in individuals with autism spectrum disorder. Autism, 19(5), 622–636.CrossRef

Azari, P., Lindsay, D. R., Briones, D., Clarke, C., Buchheit, T., & Pyati, S. (2012). Efficacy and safety of ketamine in patients with complex regional pain syndrome: A systematic review. CNS Drugs, 26, 215–228. https://doi.org/10.2165/11595200-000000000-00000.CrossRefPubMed

Baio, J. (2012). Prevalence of Autism Spectrum Disorders: Autism and Developmental Disabilities Monitoring Network, 14 Sites, United States, 2008. Morbidity and Mortality Weekly Report. Surveillance Summaries. Volume 61, Number 3. Centers for Disease Control and Prevention.

Belsito, K. M., Law, P. A., Kirk, K. S., Landa, R. J., & Zimmerman, A. W. (2001). Lamotrigine therapy for autistic disorder: A randomized, double-blind, placebo-controlled trial. Journal of Autism and Developmental Disorders, 31, 175–181.CrossRef

Berman, R. M., et al. (2000). Antidepressant effects of ketamine in depressed patients. Biological Psychiatry, 47, 351–354.CrossRef

Bremner, J. D., et al. (1998). Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). Journal of Traumatic Stress, 11, 125–136. https://doi.org/10.1023/A:1024465317902.CrossRefPubMed

Carlson, G. C. (2012). Glutamate receptor dysfunction and drug targets across models of autism spectrum disorders. Pharmacology, Biochemistry, and Behavior, 100, 850–854. https://doi.org/10.1016/j.pbb.2011.02.003.CrossRefPubMed

Carr, D. B., et al. (2004). Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: A randomized, double-blind, placebo-controlled, crossover study. Pain, 108, 17–27. https://doi.org/10.1016/j.pain.2003.07.001.CrossRefPubMed

Choudhury, P. R., Lahiri, S., & Rajamma, U. (2012). Glutamate mediated signaling in the pathophysiology of autism spectrum disorders. Pharmacology, Biochemistry, and Behavior, 100, 841–849. https://doi.org/10.1016/j.pbb.2011.06.023.CrossRefPubMed

Constantino, J. N., et al. (2003). Validation of a brief quantitative measure of autistic traits: Comparison of the social responsiveness scale with the autism diagnostic interview-revised. Journal of Autism and Developmental Disorders, 33, 427–433.CrossRef

Correia, C. T., et al. (2010). Increased BDNF levels and NTRK2 gene association suggest a disruption of BDNF/TrkB signaling in autism. Genes, Brain, and Behavior, 9, 841–848. https://doi.org/10.1111/j.1601-183X.2010.00627.x.CrossRefPubMed

Erickson, C. A., Posey, D. J., Stigler, K. A., & McDougle, C. J. (2008). Glutamatergic function in autism. In U. Heresco-Levy (Ed.), Glutamate in Neuropsychiatric Disorders (pp. 197–212). Trivandrum: Research Signpost.

Esbensen, A. J., Rojahn, J., Aman, M. G., & Ruedrich, S. (2003). Reliability and validity of an assessment instrument for anxiety, depression, and mood among individuals with mental retardation. Journal of Autism and Developmental Disorders, 33, 617–629.CrossRef

Ethridge, L. E., et al. (2017). Neural synchronization deficits linked to cortical hyper-excitability and auditory hypersensitivity in fragile X syndrome. Molecular Autism, 8, 22. https://doi.org/10.1186/s13229-017-0140-1.CrossRefPubMedPubMedCentral

Fung, L. K., Libove, R. A., Phillips, J., Haddad, F., & Hardan, A. Y. (2014). Brief report: An open-label study of the neurosteroid pregnenolone in adults with autism spectrum disorder. Journal of Autism and Developmental Disorders, 44(11), 2971–2977.CrossRef

Green, S. M., Clark, R., Hostetler, M. A., Cohen, M., Carlson, D., & Rothrock, S. G. (1999a). Inadvertent ketamine overdose in children: Clinical manifestations and outcome. Annals of emergency medicine, 34, 492–497.CrossRef

Green, S. M., & Krauss, B. (2004). Clinical practice guideline for emergency department ketamine dissociative sedation in children. Annals of emergency medicine, 44, 460–471. https://doi.org/10.1016/S0196064404006365.CrossRefPubMed

Green, S. M., Roback, M. G., Kennedy, R. M., & Krauss, B. (2011). Clinical practice guideline for emergency department ketamine dissociative sedation: 2011 update. Annals of emergency medicine, 57, 449–461. https://doi.org/10.1016/j.annemergmed.2010.11.030.CrossRefPubMed

Green, S. M., et al. (2009a). Predictors of airway and respiratory adverse events with ketamine sedation in the emergency department: An individual-patient data meta-analysis of 8,282 children. Annals of Emergency Medicine, 54(158–68), e1–4. https://doi.org/10.1016/j.annemergmed.2008.12.011.CrossRef

Green, S. M., et al. (2009b). Predictors of emesis and recovery agitation with emergency department ketamine sedation: An individual-patient data meta-analysis of 8,282 children. Annals of Emergency Medicine, 54(171–80), e1–4. https://doi.org/10.1016/j.annemergmed.2009.04.004.CrossRef

Green, S. M., Rothrock, S. G., Hestdalen, R., Ho, M., & Lynch, E. L. (1999b). Ketamine sedation in mentally disabled adults. Academic Emergency Medicine, 6, 86–87.CrossRef

Grzadzinski, R., et al. (2016). Measuring changes in social communication behaviors: Preliminary development of the brief observation of social communication change (BOSCC). Journal of Autism and Developmental Disorders, 46, 2464–2479. https://doi.org/10.1007/s10803-016-2782-9.CrossRefPubMed

Guy, W. (1976). ECDEU assessment manual for psychopharmacology, Publication No. 76-338. Washington, DC: U.S. DHEW, NIMH.

Interagency Autism Coordinating Committee. (2010). IACC strategic plan for autism spectrum disorder research. Washington (DC): US Department of Health and Human Services, 66, 2011.

Jones, B., & Kenward, G. (2015). Design and analysis of cross-over trials. Boca Raton, FL: CRC Press.

King, B. H., et al. (2009). Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Archives of General Psychiatry, 66, 583–590. https://doi.org/10.1001/archgenpsychiatry.2009.30.CrossRefPubMedPubMedCentral

King, B. H., et al. (2001). Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 40, 658–665.CrossRef

Krystal, J. H., Sanacora, G., & Duman, R. S. (2013). Rapid-acting glutamatergic antidepressants: The path to ketamine and beyond. Biological Psychiatry, 73, 1133–1141. https://doi.org/10.1016/j.biopsych.2013.03.026.CrossRefPubMedPubMedCentral

Lapidus, K. A., et al. (2014). A randomized controlled trial of intranasal ketamine in major depressive disorder. Biological Psychiatry, 76, 970–976. https://doi.org/10.1016/j.biopsych.2014.03.026.CrossRefPubMedPubMedCentral

Lara, D. R., Bisol, L. W., & Munari, L. R. (2013). Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression. International Journal of Neuropsychopharmacology, 16, 2111–2117. https://doi.org/10.1017/S1461145713000485.CrossRef

Lord, C., Rutter, M., DiLavore, P., Risi, S., Gotham, K., & Bishop, S. (2012). Autism diagnostic observation schedule–2nd edition (ADOS-2). Los Angeles, CA: Western Psychological Corporation.

Luckenbaugh, D. A., et al. (2014). Do the dissociative side effects of ketamine mediate its antidepressant effects? Journal of Affective Disorders, 159, 56–61. https://doi.org/10.1016/j.jad.2014.02.017.CrossRefPubMedPubMedCentral

Malinovsky, J. M., Servin, F., Cozian, A., Lepage, J. Y., & Pinaud, M. (1996). Ketamine and norketamine plasma concentrations after i.v., nasal and rectal administration in children. British Journal of Anaesthesia, 77, 203–207.CrossRef

Marshburn, E. C., & Aman, M. G. (1992). Factor validity and norms for the Aberrant Behavior Checklist in a community sample of children with mental retardation. Journal of Autism and Developmental Disorders, 22(3), 357–373.CrossRef

McCracken, J. T., et al. (2002). Risperidone in children with autism and serious behavioral problems. New England Journal of Medicine, 347, 314–321. https://doi.org/10.1056/NEJMoa013171.CrossRef

Minshawi, N., et al. (2015). A randomized, Placebo-Controlled Trial of D-cycloserine for the enhancement of social skills training in autism spectrum disorders. Molecular Autism. In press

Minshawi, N. F., et al. (2016). A randomized, placebo-controlled trial of D-cycloserine for the enhancement of social skills training in autism spectrum disorders. Molecular Autism, 7, 2. https://doi.org/10.1186/s13229-015-0062-8.CrossRefPubMedPubMedCentral

Mion, G., & Villevieille, T. (2013). Ketamine pharmacology: An update (pharmacodynamics and molecular aspects, recent findings). CNS Neuroscience & Therapeutics, 19, 370–380. https://doi.org/10.1111/cns.12099.CrossRef

Norris, M., Aman, M. G., Mazurek, M. O., Scherr, J. F., & Butter, E. M. (2019). Psychometric characteristics of the aberrant behavior checklist in a well-defined sample of youth with autism spectrum disorder. Research in Autism Spectrum Disorders, 62, 1–9.CrossRef

Orser, B. A., Pennefather, P. S., & MacDonald, J. F. (1997). Multiple mechanisms of ketamine blockade of N-methyl-D-aspartate receptors. Anesthesiology, 86, 903–917.CrossRef

Owen, R., et al. (2009). Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics, 124, 1533–1540. https://doi.org/10.1542/peds.2008-3782.CrossRefPubMed

Papolos, D. F., Teicher, M. H., Faedda, G. L., Murphy, P., & Mattis, S. (2013). Clinical experience using intranasal ketamine in the treatment of pediatric bipolar disorder/fear of harm phenotype. Journal of Affective Disorders, 147, 431–436. https://doi.org/10.1016/j.jad.2012.08.040.CrossRefPubMed

Posey, D., et al. (2009). A double-blind, placebo-controlled trial of N-acetylcysteine in children with autism spectrum disorders. In American College of Neuropsychopharmacology, 48th Annual Meeting. p. 208

Posey, D. J., Stigler, K., Erickson, C. A., Azzouz, F., Mullett, J., Diener, J. T., & McDougle, C. J. (2008a). A double-blind, placebo-controlled study of D-Cycloserine in children with autistic disorder. In Chicago: Annual Meeting of the American Academy of Child and Adolescent Psychiatry (p. 219).

Posey, D. J., Erickson, C. A., & McDougle, C. J. (2008b). Developing drugs for core social and communication impairment in autism. Child and Adolescent Psychiatric Clinics of North America, 17, 787–801.CrossRef

Posey, D. J., Kem, D. L., Swiezy, N. B., Sweeten, T. L., Wiegand, R. E., & McDougle, C. J. (2004). A pilot study of D-cycloserine in subjects with autistic disorder. American Journal of Psychiatry, 161, 2115–2117.CrossRef

Randolph, C., Tierney, M. C., Mohr, E., & Chase, T. N. (1998). The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): Preliminary clinical validity. Journal of Clinical and Experimental Neuropsychology, 20, 310–319. https://doi.org/10.1076/jcen.20.3.310.823.CrossRefPubMed

Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. (2005). Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Archives of General Psychiatry, 62(11), 1266–1274. https://doi.org/10.1001/archpsyc.62.11.1266.CrossRef

Scahill, L., Hallett, V., Aman, M. G., McDougle, C. J., Arnold, L. E., McCracken, J. T., et al. (2013). Brief Report: Social disability in autism spectrum disorder: results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network trials. Journal of Autism and Developmental Disorders, 43(3), 739–746.CrossRef

Uzunova, G., Hollander, E., & Shepherd, J. (2014). The role of ionotropic glutamate receptors in childhood neurodevelopmental disorders: Autism spectrum disorders and fragile x syndrome. Current Neuropharmacology, 12, 71–98. https://doi.org/10.2174/1570159X113116660046.CrossRefPubMedPubMedCentral

Vermeulen, E., van den Anker, J. N., DellaPasqua, O., Hoppu, K., van der Lee, J. H., & Global Research in Paediatrics (GRiP). (2017). How to optimise drug study design: Pharmacokinetics and pharmacodynamics studies introduced to paediatricians. Journal of Pharmacy and Pharmacology, 69(4), 439–447.CrossRef

Wang, H., & Doering, L. C. (2013). Reversing autism by targeting downstream mTOR signaling. Frontiers in Cell Neuroscience, 7, 28. https://doi.org/10.3389/fncel.2013.00028.CrossRef

Wink, L. K., et al. (2016). A randomized placebo-controlled pilot study of N-acetylcysteine in youth with autism spectrum disorder. Molecular Autism, 7, 26. https://doi.org/10.1186/s13229-016-0088-6.CrossRefPubMedPubMedCentral

Wink, L. K., et al. (2017). d-Cycloserine enhances durability of social skills training in autism spectrum disorder. Molecular Autism, 8, 2. https://doi.org/10.1186/s13229-017-0116-1.CrossRefPubMedPubMedCentral

Wink, L. K., et al. (2014). Intranasal ketamine treatment in an adult with autism spectrum disorder. The Journal of Clinical Psychiatry, 75, 835–836. https://doi.org/10.4088/JCP.13cr08917.CrossRefPubMed

Yanagihara, Y., et al. (2003). Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers. Biopharmaceutics & Drug Disposition, 24, 37–43. https://doi.org/10.1002/bdd.336.CrossRef

Zanos, P., & Gould, T. D. (2018). Mechanisms of ketamine action as an antidepressant. Molecular Psychiatry, 23, 801–811. https://doi.org/10.1038/mp.2017.255.CrossRefPubMedPubMedCentral

Zarate, C. A., Jr., et al. (2012). Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biological Psychiatry, 71, 939–946. https://doi.org/10.1016/j.biopsych.2011.12.010.CrossRefPubMedPubMedCentral

Zarate, C. A., Jr., et al. (2006). A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry, 63, 856–864. https://doi.org/10.1001/archpsyc.63.8.856.CrossRefPubMed

Titel: Brief Report: Intranasal Ketamine in Adolescents and Young Adults with Autism Spectrum Disorder—Initial Results of a Randomized, Controlled, Crossover, Pilot Study
Auteurs: Logan K. Wink
Debra L. Reisinger
Paul Horn
Rebecca C. Shaffer
Kaela O’Brien
Lauren Schmitt
Kelli R. Dominick
Ernest V. Pedapati
Craig A. Erickson
Publicatiedatum: 08-07-2020
Uitgeverij: Springer US
Gepubliceerd in: Journal of Autism and Developmental Disorders / Uitgave 4/2021
Print ISSN: 0162-3257
Elektronisch ISSN: 1573-3432
DOI: https://doi.org/10.1007/s10803-020-04542-z

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Log in om toegang te krijgen

Andere artikelen Uitgave 4/2021

Repetitive Behavior in Children and Adolescents: Psychometric Properties of the German Version of the Repetitive Behavior Scale-Revised

Development and Feasibility of MindChip™: A Social Emotional Telehealth Intervention for Autistic Adults

Self-Compassion in Mothers of Children with Autism Spectrum Disorder: A Qualitative Analysis

Delay to Early Intensive Behavioral Intervention and Educational Outcomes for a Medicaid-Enrolled Cohort of Children with Autism

An Assessment of the Psychometric Properties of the GHQ-12 in an English Population of Autistic Adults Without Learning Difficulties

Health Factors, Sociability, and Academic Outcomes of Typically Developing Youth and Youth with Autism Spectrum Disorder: A Latent Class Analysis Approach